Sep 07, 2026
Novartis (NVS) Stock Drops 3% as Pelacarsen Heart Drug Disappoints in Key Trial
Novartis (NVS) stock dropped 3% after pelacarsen failed its cardiovascular outcomes trial, raising concerns about Lp(a)-targeting therapies.
The post Novartis (NVS) Stock Drops 3% as Pelacarsen Heart Drug Disappoints in Key Trial appeared first on Blockonomi.
Source: Blockonomi →Related News
- 3 hours ago
Ionis Pharmaceuticals, Inc. (IONS) Stock: Surges as Phase 3 ALS Trial Delivers P...
- 4 hours ago
PayPal Holdings, Inc. (PYPL) Stock: Muse Partnership Opens New AI Commerce Route
- 4 hours ago
Amazon.com, Inc. (AMZN) Stock: Amazon Blocks Meta’s Muse Shopping Agent
- 5 hours ago
SpaceX (SPCX) Stock: Advances as Merger Speculation Drives Attention
- 6 hours ago
NVIDIA (NVDA) Stock: Gains as Apple Challenges Cloud AI With New Macs